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Abstract
In an attempt to develop better therapeutic approaches for metastatic renal cell carcinoma (RCC), the combination of
the antiangiogenic drug sunitinib with gemcitabine was studied. Using dynamic contrast-enhanced magnetic reso-
nance imaging (DCE-MRI), we have previously determined that a sunitinib dosage of 20 mg/kg per day increased
kidney tumor perfusion and decreased vascular permeability in a preclinical murine RCCmodel. This sunitinib dosage
causing regularization of tumor vessels was selected to improve delivery of gemcitabine to the tumor. DCE-MRI was
used to monitor regularization of vasculature with sunitinib in kidney tumors to schedule gemcitabine. We estab-
lished an effective and nontoxic schedule of sunitinib combined with gemcitabine consisting of pretreatment with
sunitinib for 3 days followed by four treatments of gemcitabine at 20 mg/kg given 3 days apart while continuing daily
sunitinib treatment. This treatment caused significant tumor growth inhibition resulting in small residual tumor no-
dules exhibiting giant tumor cells with degenerative changes, which were observed both in kidney tumors and in
spontaneous lung metastases, suggesting a systemic antitumor response. The combined therapy caused a signif-
icant increase in mouse survival. DCE-MRI monitoring of vascular changes induced by sunitinib, gemcitabine, and
both combined showed increased tumor perfusion and decreased vascular permeability in kidney tumors. These
findings, confirmed histologically by thinning of tumor blood vessels, suggest that both sunitinib and gemcitabine
exert antiangiogenic effects in addition to cytotoxic antitumor activity. These studies show that DCE-MRI can be used
to select the dose and schedule of antiangiogenic drugs to schedule chemotherapy and improve its efficacy.
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Introduction
Recent developments in antiangiogenic therapy have improved target-
ing metastatic renal cell carcinoma (RCC). The incidence of RCC
has increased in recent years, with approximately 54,390 new cases
each year in the United States. The disease is responsible for an esti-
mated 13,010 deaths each year [1]. Nearly half of the patients present
with localized disease that can be treated by surgical removal [2,3].
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However, one third of the patients have metastatic disease at first pre-
sentation, and 20% to 30% of the patients treated for localized RCC
subsequently develop metastatic disease that frequently involves the
lungs [2,3].
The drug sunitinib (SU11248 or Sutent) is a small molecule re-
ceptor tyrosine kinase (RTK) inhibitor that has been approved by the
US Food and Drug Administration in January 2006 for RCC treat-
ment based on significant responses in multiple metastatic sites and in
primary tumors in initial clinical trials for metastatic RCC [4]. We and
others have demonstrated that sunitinib targets and inhibits signaling
of several RTKs including platelet-derived growth factor receptor, vas-
cular endothelial growth factor receptor, c-kit protooncogene, and
FMS-like tyrosine kinase 3 in mouse xenograft models [5]. Sunitinib
exhibits direct antitumor activity by inhibiting RTKs that are expressed
by cancer cells and are involved in signaling for cancer cell proliferation
[5–12]. Sunitinib also exhibits antiangiogenic activity by inhibition of
signaling through vascular endothelial growth factor receptor 2 and
platelet-derived growth factor receptor-β RTKs expressed on endothe-
lial cells or stromal cells [6,13].
In a phase 3 multinational study of 750 patients with metastatic
RCC, randomized to sunitinib or interferon α (IFNα), the response
rate to sunitinib was 31%, with a median progression-free survival
(PFS) of 11.7 months and a median survival of 28 months [14]. A
recent update of this trial documented an objective response rate of
47% with 11 months of median PFS for sunitinib versus 12% objec-
tive response rate and 5 months of PFS for IFNα [15]. Although the
results with sunitinib therapy are impressive, long-term control of the
disease is still not achieved. In addition, several trials documented
adverse effects of cardiotoxicity in some of the patients probably as
a result of alterations to normal vasculature [16–19]. Therefore, fur-
ther investigations with sunitinib dose adjustments and combination
with other cytotoxic drugs are warranted to decrease the effect on
vital organs such as the heart and the kidney.
The process of tumor angiogenesis involves proliferation of abnor-
mal vessels that are enlarged, disorganized, and leaky because of de-
fective basement membrane. These structural defects of tumor vessels
cause increased interstitial tissue pressure, impaired blood supply, and
decreased oxygen supply in tumors compromising the delivery and
efficacy of cytotoxic drugs and radiotherapy [20,21]. To increase
the efficacy of chemotherapy, we have recently investigated various
doses of sunitinib to cause only partial destruction of immature and
inefficient blood vessels leading to “normalization” of tumor vascu-
lature and improve the blood flow in tumors [5]. We used dynamic
contrast-enhanced magnetic resonance imaging (DCE-MRI) to im-
age vascular changes induced by sunitinib within the tumor, in an
orthotopic KCI-18 model of human RCC xenografts in nude mice.
DCE-MRI is a noninvasive approach, currently used in humans, that
can detect early changes in the tumor induced by antiangiogenic ther-
apy as reported in human studies [22–25] and in preclinical animal
models [26,27]. This method measures a combination of tumor per-
fusion and vessel permeability and allows the detection of changes
in tumor vascularity, which occur at a much earlier stage in the treat-
ment of tumors with antiangiogenic drugs than does shrinkage of
tumor mass [23,25].
By assessing vascular changes by DCE-MRI, we showed that a
suboptimal daily sunitinib dosage of 20 mg/kg per day mildly affected
normal vessels but caused better tumor perfusion and decreased
vascular permeability, in agreement with histologic observations of
thinning and regularization of tumor vessels [5]. The goals of the
current study were to determine whether using sunitinib at doses that
regularize the blood flow in the tumor in conjunction with the cyto-
toxic drug gemcitabine could improve its therapeutic efficacy for
RCC. Gemcitabine is a pyrimidine analog that inhibits DNA syn-
thesis. The antitumor activity of gemcitabine depends on a series of
sequential phosphorylations leading to accumulation of gemcitabine
diphosphate and triphosphate that interfere with DNA elongation
by competing with dCTP and also inhibit ribonucleotide reductase,
thus reducing the pool of deoxyribonucleotide triphosphates. A few
clinical trials have used gemcitabine in combination with other chemo-
therapy drugs including fluorouracil, thalidomide, and capecitabine
or with the cytokine IFNα for metastatic RCC [28–31]. These trials
resulted in modest clinical benefit.
Although gemcitabine is a potent antitumor drug, its activity may be
reduced by poor access to tumor cells caused by tumor vessel leaki-
ness and increased interstitial tissue pressure [20,21]. In the current
study, we have investigated whether improving blood flow by sunitinib,
at doses that regularize tumor vessels, could enhance the efficacy of
gemcitabine for RCC in murine xenografts kidney tumors. DCE-
MRI was used to monitor vascular changes induced by pretreating with
sunitinib in KCI-18 kidney tumors to schedule initiation of chemo-
therapy. We determined the dose and schedule of the combination of
antiangiogenic therapy with sunitinib and cytotoxic therapy with gem-
citabine that result in significant long-lasting antitumor response. Vas-
cular changes caused by gemcitabine treatment as a single modality or
combined with sunitinib were evaluated by DCE-MRI.
Materials and Methods
Orthotopic KCI-18/IK RCC Tumor Model
The human RCC cell line designated KCI-18 was established in
our laboratory from a primary renal tumor specimen obtained from a
patient with papillary RCC (nuclear grade 3/4) [32]. Cells were cul-
tured in Dulbecco’s modified Eagle medium with supplements [32].
After serial passages of KCI-18 cells in the kidney of nude mice,
highly tumorigenic KCI-18/IK RCC cell lines were generated [32].
KCI-18/IK cells were washed with Hank’s balanced salt solution and
subcapsularly injected at a concentration of 5 × 105 cells in 30 μl of
Hank’s balanced salt solution in the right kidney in 5- to 6-week-old
female BALB/C nu/nu nude mice (Harlan, Indianapolis, IN) [32].
Mice were housed and handled under sterile conditions in facilities
accredited by the American Association for the Accreditation of Lab-
oratory Animal Care. The animal protocol was approved by Wayne
State University Animal Investigation Committee.
Experimental Protocol
After injection of KCI-18/IK cells, a few mice were killed at early
time points to assess tumor growth before initiating treatment. Small
tumors were detectable by days 9 to 10 in the kidney. On day 10, mice
bearing established kidney tumors were treated with sunitinib (Pfizer,
Inc, New York, NY). The drug was prepared in a carboxymethyl cel-
lulose suspension vehicle, at a dosage of 20 mg/kg per day (SU20) and
given orally by gavage [5]. Control mice were treated with vehicle only.
After sunitinib pretreatment for 3 days, mice were treated with various
doses of gemcitabine administered two to three times a week by intra-
peritoneal (i.p.) injections. Gemcitabine (Gemzar; Eli Lilly, Indianapolis,
IN) was reconstituted in PBS and prepared at doses of 10 to 50 mg/kg.
Sunitinib treatment was continued daily for the duration of the ex-
periment. To assess the therapeutic response of kidney tumors to a
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combination of sunitinib and gemcitabine, six to eight mice per ex-
perimental group were treated. Mice were killed by day 28 after tumor
cell injection, when the tumor burden in control animals was large
(>1.5 cm × 1 cm in size compared with 0.7 cm × 0.25 cm for nor-
mal kidney) compared with the tumor sizes in treated groups [5].
The tumor-bearing right kidneys and the contralateral left normal
kidneys were resected and weighed [5]. For survival studies, 12 mice
per experimental group were treated with sunitinib at 20 mg/kg per
day for 3 days on days 10 to 12 after KCI-18 cell injection in the kid-
ney. Then, mice received five gemcitabine treatments at 20 mg/kg
given 3 to 4 days apart, on days 13, 16, 20, 23, and 27. Sunitinib
was continued daily for 5 d/wk, for 6 weeks, up to 50 days. Mice were
monitored daily for survival, and sick animals were killed and autopsied
[33]. On day 50, all remaining mice were killed, and tumor-bearing
kidneys were resected and weighed.
Tissue Preparation for Histology
At the completion of experiments, mice were killed, and tumor-
bearing kidneys, normal contralateral kidneys, and the lungs were
resected and processed for histology. All tissues were fixed in 10%
buffered formalin, embedded in paraffin, and sectioned [5]. Sections
were stained with hematoxylin-eosin (H&E) [5].
DCE-MRI Monitoring of Tumor Perfusion and Permeability
and Tumor Size in Kidney Tumors
On the basis of the initial experiments, early time points between
3 and 11 days after initiation of sunitinib treatment (day 14 through
day 21 after tumor cell implantation) were selected for DCE-MRI
studies to avoid incorrect analysis of advanced and large necrotic tu-
mors in control mice [5]. Three mice from control-, sunitinib-, and
gemcitabine-treated groups were imaged byDCE-MRI.Mice were anes-
thetized by i.p. injections of 0.35 ml of pentobarbital and 0.35 ml
of ketamine at a concentration of 52.5 mg/kg and then a catheter was
inserted into their tail vein, which was attached to a syringe contain-
ing Gd-DTPA contrast agent (Berlex, Wayne, NJ). Mice were posi-
tioned on a cradle heated by temperature-controlled water and were
given a second low dose of 15 mg/kg anesthetics (in 0.1 ml volume)
to avoid motion problems while in the magnet [5]. A 2-cm-diameter
receive-only surface coil was placed over the tumor, and the cradle was
placed inside an 11-cm-inner-diameter transmit-only volume coil.
DCE-MRI of mice was performed in the MR Research Facility at
Wayne State University, using a Bruker Biospec AVANCE animal scan-
ner (Bruker, Karlsruhe, Germany) equipped with a 4.7-T horizontal
bore magnet and actively shielded gradients. Anatomic imaging was
done using a two-dimensional T2-weighted spin-echo scan (repetition
time [TR] = 2000 milliseconds, echo time [TE] = 52.4 milliseconds)
to get an overview of the kidney [5]. Baseline imaging data of the kid-
neys were obtained using the short-TR DCE scan for 30 time points
(7 seconds between time points).On time point 10, 100μl ofGd-DTPA
(0.125 mmol/kg) was injected into the tail vein catheter. This dose
was selected based on preliminary Gd dose-searching experiments to
obtain appropriate contrast for image analysis [5]. Then, imaging data
were acquired for 20 more time points. The imaging parameters for
this multislice two-dimensional gradient echo scan were as follows:
TR = 54.7 milliseconds, TE = 2.9 milliseconds, flip angle = 30°, field
of view = 32 mm × 32 mm, slice thickness = 1.5 mm with 0.5 mm
gap, matrix size = 128 × 128. Five slices were collected for each animal.
Data were processed to determine changes in contrast agent uptake
using the SPIN DCE software (Detroit, MI) [34]. For data analysis,
the full kidney was selected as the region of interest (ROI) for the
tumor-bearing kidney and the contralateral left normal kidney. A thresh-
old was selected to remove noise-only pixels in the image [5]. Gd con-
centrations [C (t)] in the tissue were calculated for all pixels in the
ROI and for each time point [34]. Data from the C (t) curves were
compiled for each pixel for 16 time points (112 seconds) after Gd in-
jection to create the initial area under the curve (IAUC). The distribu-
tion of IAUC for the entire ROI is then shown as a means to visualize
the effects in every pixel in a single plot. The CIAUC is the cumulative
initial area under the curve of the IAUC histogram [5]. For quantita-
tive analysis of vascular permeability, R50 (median) values are derived
from CIAUC curves and corresponded to the concentration of Gd at
which 50% of the pixels have been included [34]. To evaluate the
uptake, washout, and leakage of Gd into the tumor and surrounding
kidney tissue, the parametric color maps are used to show the total Gd
uptake (AUC) in individual structures. The parameters measured in
DCE-MRI for sunitinib- and/or gemcitabine-treated tumors were
compared with those obtained for control tumors and normal kidneys.
Analysis of Cell Survival In Vitro by Clonogenic Assay
KCI-18 cells were treated for 24 hours with 1 μM sunitinib or
gemcitabine at 1 and 2.5 nM or both drugs combined. Cells were
plated in a colony formation assay in triplicate wells of six-well plates
at 500 cells per well for control, at 1000 cells per well for sunitinib
or gemcitabine alone, and at 3000 cells per well for sunitinib + gem-
citabine combined treatment [35]. These plating conditions and drug
concentrations were determined based on dose titration experiments.
The drugs were added to the cells in the colony plates, and cells were
incubated for 10 days at 37°C in a 5% CO2/5% O2/90% N2 in-
cubator. Colonies were fixed, stained, and counted as previously de-
scribed [35]. The plating efficiency was calculated for each well, and
the surviving fraction was normalized to control cells [35].
Statistical Analysis
Evaluation of the shape of the frequency distribution of tumor
weights indicated that a log transformation was required to meet
the assumptions of normal theory tests. Linear models were used
to assess the statistical significance of differences in tumor weight be-
tween experimental groups, and proportional hazards models were
used for survival data. In both models, indicator variables were used
to parameterize dose. Adjustment for multiple comparisons between
treatments was made using Holm’s procedure to protect against in-
flated type 1 errors [35,36]. Kaplan-Meier methods were used to
graphically compare survival in each of the groups. The log-rank test
was used to test differences in survival distributions between groups
again using Holm’s procedure to control for type 1 error rate.
Results
Direct Cytotoxic Effect of Sunitinib Combined with
Gemcitabine in KCI-18 Cells In Vitro
We have previously shown that sunitinib exerts a direct cytotoxic
effect on KCI-18 RCC in vitro, in a dose-dependent manner [5]. We
found that a dose of 1 μM sunitinib caused a significant 40% inhi-
bition in cell survival in a clonogenic assay, as confirmed in this ad-
ditional experiment (Table 1). This dose was selected to investigate
whether this effect is enhanced by the addition of gemcitabine. After
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pilot titration experiments, suboptimal doses of gemcitabine were
tested alone and combined with sunitinib in a clonogenic assay.
Gemcitabine at doses of 1 and 2.5 μM caused significant inhibition
of KCI-18 cell survival of approximately 50% (P < .001) and 70%
(P < .0001), respectively, compared with control cells treated with
vehicle (Table 1). This cell growth inhibition was significantly en-
hanced to 80% and 90% by cotreatment of 1 μM sunitinib with
1 μM and 2.5 μM gemcitabine compared with gemcitabine alone
(P < .01) and sunitinib alone (P < .01) and with control cells (P <
.0001; Table 1).
Therapeutic Response of Kidney Tumors by Combined
Sunitinib and Gemcitabine In Vivo
Using DCE-MRI and histologic studies, we have previously dem-
onstrated that sunitinib, given at a dosage of 20 mg/kg per day for
7 days, caused trimming and regularization of tumor vessels with im-
proved tumor perfusion [5]. This dosage was therefore selected for
combination with chemotherapy. To schedule administration of gem-
citabine, mice, which had established kidney tumors (mean ± SD;
150 ± 7 mm3, 186 ± 4 mg) compared with normal kidney sizes
(125 ± 2 mm3, 148 ± 12 mg) on day 10 after tumor implantation,
were treated daily with sunitinib at 20 mg/kg per day (SU20) for
3 days and then imaged by DCE-MRI (Figure 1A). As observed in
our previous studies, the IAUC distribution pattern of Gd uptake
and clearance in control mice were different for kidney tumors than
for normal kidneys [5]. Slower clearance of Gd was observed in the
tumor-bearing kidney compared with faster clearance in the normal
kidney, and the CIAUC curve for the tumor-bearing kidney showed
a pronounced shift to the right compared with normal kidney, indic-
ative of a greater retention of Gd (Figure 1A). In contrast, treatment
with SU20 for 3 days showed identical patterns of Gd uptake and
clearance in the kidney tumor than in the normal kidney, as previ-
ously shown [5]. IAUC and CIAUC histograms of the kidney tumor
overlapped those of the normal kidney and shifted to the left com-
pared with control tumor kidneys, indicating decreased Gd retention
and improved tumor perfusion (Figure 1A). On the basis of these
data showing that vascular regularization is detectable by DCE-
MRI after 3 days of daily treatment with SU20, we designed the
treatment schedule for combination therapy with gemcitabine as pre-
sented in Figure 1B. Gemcitabine treatment was initiated at 3 days
after pretreatment with SU20 for established KCI-18 kidney tumors.
The schedule and dose of gemcitabine treatment were determined
based on dose titration experiments. After three to five injections
of gemcitabine at the dose of 50 mg/kg, given 2 days apart, together
with daily SU20, a complete tumor growth inhibition was observed,
but this treatment was too toxic to the mice, resulting in 50% death.
Therefore, we tested lower doses of 10, 20, and 40 mg/kg of gem-
citabine (G10, G20, and G40) given twice a week, 3 days apart,
whereas SU20 was continued daily for the duration of the experi-
ment (Figure 1B). In separate experimental groups of six to eight
mice per group, the response to gemcitabine treatment alone was com-
pared with SU20 alone and both combined in a relatively short-term
experiment of 28 days, to compare tumor size at a time point when
control tumors are very large. The tumor-bearing right kidney and
the normal left kidney were weighed, and the mean tumor weights
were compared between each treatment group and control group
(Figure 1C). After SU20 treatment alone, kidney tumors were signif-
icantly smaller by 43% compared with control mice tumors (P =
.001), but these tumors were still large (Figure 1C), as previously re-
ported [5]. Compared with the control, treatment with G10 caused
approximately 30% inhibition (P = .04) and increased to 52.5% when
combined with SU20 (P < .001). The effect of G20 was even greater,
causing 64% tumor growth inhibition (P < .001) and 74% when com-
bined with SU20 (P < .001; Figure 1C ). Although the difference
in the mean tumor weight of G20 + SU20 was not significant com-
pared with G20 (P = .33), the tumor weight data (n = 8) in the com-
bined treatment were more consistent and less variable than with G20
only. The mean weight of tumor-bearing kidneys of mice treated with
SU20 + G20 was only 223 ± 37 mg, and their shape and size con-
sistently looked closer to those of normal kidneys (166 ± 22 mg) with
a mean difference of only 57 mg (Figure 1C ). This combined therapy
using 20 mg/kg per day of sunitinib combined with four treatments
of gemcitabine at 20 mg/kg given 3 days apart for a total of 80 mg/kg
did not cause any signs of toxicity to the mice. However, when the dose
of gemcitabine was increased to 40 mg/kg, for a total of 160 mg alone
or together with SU20, it was associated with toxicity and weight
loss. Treatment with G40 resulted in significant tumor growth inhibi-
tion of 71% (P < .001) when given alone, but no further increase
was observed with combination with SU20 compared with G40 alone
(P = .53; Figure 1C). The difference between the G20 and G40 groups
was not statistically significant (P = .51). It should be noted that
the size of the normal contralateral kidneys was not affected by the
single or combined therapy at every dose of gemcitabine tested (Fig-
ure 1C , inset).
Survival of Kidney Tumor–Bearing Mice Treated with
Combined Sunitinib and Gemcitabine
From the experiments presented in Figure 1, we have determined
the sequence, schedule, and doses for a safe and therapeutic combina-
tion of sunitinib and gemcitabine for treating KCI-18 kidney tumor–
bearing mice. We showed that a dosage of sunitinib of 20 mg/kg
per day combined with gemcitabine at 20 mg/kg per treatment for
four treatments results in optimal and consistent tumor growth inhi-
bition, when this effect was assessed on day 28 after tumor implanta-
tion (Figure 1C). These conditions were selected to evaluate the effect
of single and combined therapies on mouse survival during a longer-
term experiment of 50 days. Mice bearing established kidney tumors
were pretreated with 20 mg/kg per day sunitinib for 3 days (days 10-
12) followed by four injections of gemcitabine at 20 mg/kg given
3 days apart (days 13, 16, 20, and 23) following the same schedule
shown in Figure 1B. An additional gemcitabine injection was admin-
istered on day 23 because of the longer duration of the experiment.
Table 1. Inhibition of KCI-18 Cell Growth by Sunitinib Combined with Gemcitabine In Vitro.
Treatment Survival Fraction (Mean ± SD) % Inhibition
Control 1.00 0
Gemcitabine (1 nM) 0.52 ± 0.04* 48
Gemcitabine (2.5 nM) 0.21 ± 0.01* 79
Sunitinib (1 μM) 0.64 ± 0.02* 36
Gemcitabine (1 nM) + Sutent (1 nM) 0.19 ± 0.01† 81
Gemcitabine (2.5 nM) + Sutent (2.5 μM) 0.07 ± 0.02† 93
KCI-18 cells were treated with gemcitabine at 1 and 2.5 nM or sunitinib at 1 μM or both drugs in
combination for 24 hours, and then cells were plated in a colony formation assay for 10 days. The
mean survival fraction was calculated from triplicate wells.
*P < .001.
†P < .0001.
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Sunitinib was continued daily for 5 d/wk for 6 weeks, up to day 50 (Fig-
ure 1B). Mice were monitored on a daily basis; sick mice showing
weight loss and/or limited mobility, as a result of large kidney tumors,
were killed and necropsied; and the tumor weights were measured. Sur-
vival of animals receiving sunitinib alone was not statistically different
from control mice (P = .08; median SU = 36 days; median controls =
29 days; Figure 1D). In both groups, mice had large kidney tumors at
necropsy, the mean tumor weights of control mice was 1157 ± 426 mg,
and that of sunitinib treated mice was 675 ± 226 mg. Animals treated
with gemcitabine alone for a total dose of 100 mg/kg had a median
survival of 43 days, significantly longer survival than controls (P <
.001) and than the sunitinib group (P = .009), but only 33% of the
mice survived up to day 50. These mice had large tumors with mean
weight of 794 ± 338 mg when necropsied. The combination of suni-
tinib and gemcitabine resulted in longer survival compared with con-
trol mice (P < .001) and mice treated with sunitinib (P < .001) but was
not significantly different from animals treated with gemcitabine alone
(P = .13; Figure 1D). Nevertheless, a higher proportion of 70% of
the mice (7/10) treated with the combined therapy survived by day
50 compared with 33% with gemcitabine alone and 0% with sunitinib
alone. Interestingly, these mice had large tumors with a mean of 767 ±
267 mg, probably because of the regrowth of kidney tumors, which
Figure 1. KCI-18 kidney tumor response to sunitinib combined with gemcitabine. (A) DCE-MRI of early vascular changes induced by
sunitinib. Mice bearing established kidney tumors were treated daily with sunitinib at 20 mg/kg per day (SU20) for 3 days and imaged
by DCE-MRI. (B) Treatment schedule for combination therapy. Mice bearing established kidney tumors were pretreated with sunitinib at
20 mg/kg per day (SU20) for 3 days on days 10 to 12 after KCI-18 cell injection in the kidney. Then, mice received gemcitabine treatments
at 10, 20, or 40 mg/kg given 3 days apart, twice a week for 2 weeks on days 13, 16, 20, and 23. Sunitinib was continued daily for up to
28 days for a short-term experiment (C) or for 50 days for a longer-term experiment (D). (C) Response of tumor-bearing kidneys to single
and combined therapy. On day 28, tumor-bearing kidneys and contralateral normal kidneys were resected and weighed. The weights
of the tumor-bearing kidneys and their median are reported for six to eight mice per group treated with vehicle (control) or sunitinib at
20 mg/kg per day (SU20) or gemcitabine at 10 (G10), 20 (G20), or 40 mg/kg (G40); each drug alone and in combination compared with
the normal contralateral kidney weights (NK). Inset shows weights of the normal contralateral kidneys for each treatment group. *P <
.001. (D) Survival of KCI-18 kidney tumor–bearing mice treated with sunitinib combined with gemcitabine. Mice bearing established kid-
ney tumors were pretreated with sunitinib (SU) at 20 mg/kg per day for 3 days on days 10 to 12 after KCI-18 cell injection in the kidney.
Then, mice received five gemcitabine (Gem) treatments at 20mg/kg given 3 to 4 days apart, during 3 weeks on days 13, 16, 20, 23, and 27,
and sunitinib was continued daily, 5 days per week, for up to 50 days as shown in Figure 2B. Mice were followed for survival and Kaplan-
Meier survival curves of mice treated with vehicle (Con for control) sunitinib (SU) or gemcitabine (Gem) or both combined (Gem + SU)
were constructed.
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was not controlled by maintenance therapy with sunitinib at 20 mg/kg
per day.
In Situ Effects of Sunitinib and Gemcitabine on Kidney
Tumors and Lung Metastases
Tumor-bearing kidneys and normal contralateral kidneys from mice
treated with sunitinib at 20 mg/kg per day, gemcitabine at 20 mg/kg,
and both combined were obtained on day 28 from experiments
described in Figure 1, B and C . These tissues were processed for his-
tology and H&E staining. Kidney tumors from control mice presented
as a high-grade carcinoma, consisting of tumor cells with large pleo-
morphic nuclei, prominent nucleoli, abundant eosinophilic cytoplasm,
and large cytoplasmic inclusions [5,32]. These tumors were highly
vascularized with a sinusoidal vascular pattern consisting of abnormal
enlarged vessels (Figure 2A). Focal extravasation of red blood cells
(RBCs) between tumor cells was observed probably because of the
leakiness of vessels and disrupted basement membrane as previously
reported [5,32]. Kidney tumors treated with sunitinib showed con-
siderable thinning, regularization, and organization of tumor vessels
with endothelial cells lining the vessels (Figure 2A). A marked decrease
in the number of tumor vessels was noted (Figure 2A). These findings
are consistent with our previous observations [5]. Kidney tumors of
mice treated with gemcitabine showed abnormal giant tumor cells ex-
hibiting degenerative changes in their cytoplasm and nuclei, which
were indicative of cell death (Figure 2A). These giant cells, comprising
approximately 70% of the tumor, contained cytoplasmic vacuoles
and pink eosinophilic inclusions and showed degenerative changes
in nuclei with focal karyopyknosis (Figure 2A). Compared with con-
trol tumors, the vascularity of these gemcitabine-treated tumors was
reduced and had lower numbers of enlarged vessels. A few focal en-
larged vessels were still observed along with few foci of RBC’s ex-
travasation (Figure 2A). Kidney tumors treated with sunitinib and
gemcitabine showed a higher frequency of approximately 90% ab-
normal giant tumor cells harboring the same cytoplasmic and nucleus
degenerative changes as those seen in gemcitabine alone (Figure 2A).
The tumor vessels looked more trimmed and more organized than
those seen after gemcitabine treatment alone, although focal dilatation
was still observed compared with sunitinib-treated tumors. In lower
magnifications, these tumors looked like residual small nodules mostly
consisting of giant tumor cells, which were surrounded by normal
epithelial renal cells (data not shown). The histologic diagnosis of tu-
mors treated with 40 mg/kg of gemcitabine alone or with sunitinib
was comparable to that shown in Figure 2A for tumors treated with
20 mg/kg gemcitabine.
Tissue sections from the normal contralateral left kidneys (not im-
planted with tumor) were also evaluated after single and combined
sunitinib and gemcitabine treatments (Figure 2B). Normal kidneys
from untreated control mice showed preserved kidney tissue architec-
ture with intact and regular blood vessels. As observed previously,
sunitinib at 20 mg/kg per day caused mild dilatation of a few vessels
[5]. Interestingly, gemcitabine caused dilatation of some of the ves-
sels and mild focal extravasation of RBCs (Figure 2B). After com-
bined sunitinib and gemcitabine treatment, focal areas of dilated
vessels were seen but at a lower frequency than with gemcitabine
alone (Figure 2B).
Spontaneous metastasis to the lungs from primary KCI-18 kidney
tumors has been previously observed in this RCC metastatic model
[32]. To assess the effect of therapy on spontaneous lung metasta-
ses, lungs were resected on day 28 from kidney tumor–bearing mice
treated with sunitinib and gemcitabine and processed for H&E stain-
ing. In control kidney tumor–bearing mice, all mice presented with
metastatic lung tumor nodules showing the typical morphology of
KCI-18 RCC tumor cells with large pleomorphic nuclei and promi-
nent nucleoli (Figure 3). Areas of dilated vessels with extravasation of
RBCs were observed as seen in primary kidney tumors (Figure 3). The
average number of lung nodules was 26 per mouse consisting of a
mixture of large and small nodules. In sunitinib-treated mice, all mice
had metastatic lung nodules, but most of the nodules were very small,
often containing less than 10 cells per nodule and an average of 14 per
mouse. The lung tumor nodules showed an overall decrease in the
number of tumor cells and/or areas of tumor destruction as well as
a marked decrease in vascularization (Figure 3). Mice treated with
20 or 40 mg of gemcitabine had a lower frequency of lung nodules
detectable in three of seven mice and presenting as one to five small
lung nodules per mouse. These lung tumor nodules exhibited giant
tumor cells with cytoplasmic vacuoles, eosinophilic inclusions, and de-
generative nuclei identical to those observed in primary kidney tumors
treated with gemcitabine (Figure 3). Few trimmed vessels were seen.
The effect of combined sunitinib and gemcitabine on metastatic lung
nodules was more drastic with large areas of hyalinization and fibro-
sis and few remaining giant tumor cells with degenerative changes
(Figure 3). Lung tumor nodules were detectable only in 3 of 11 mice
treated with sunitinib combined with 20 or 40 mg/kg gemcitabine,
and most of these nodules were very small, often containing less than
five cells per nodule and large areas of fibrosis.
DCE-MRI Evaluation of Vascular Changes Induced by
Gemcitabine Treatment in Kidney Tumors
To monitor the effect of gemcitabine treatment by DCE-MRI,
mice with established kidney tumors were treated on day 13 with
gemcitabine at a safe and therapeutic dose of 20 mg/kg, given 3 to
4 days apart, as determined from experiments described in Figure 1.
Mice were then tested by DCE-MRI after one, three, or four doses of
gemcitabine (days 14, 18, and 21, respectively). For data analysis, the
full kidney was selected as the ROI for both right tumor-bearing
kidney and left normal kidney (Figure 4A). As described previously
in Figure 1A, the IAUC and CIAUC curves for the tumor-bearing
kidney in control mice showed a pronounced shift to the right com-
pared with normal kidney, indicative of a greater retention of Gd
(Figure 4, B-D). Interestingly, gemcitabine treatment caused im-
proved clearance of Gd in the tumor-bearing kidney compared with
kidney tumors from control mice (Figure 4B). This was observed by
a shift of the IAUC and CIAUC curves toward those of normal
kidneys (Figure 4, C and D). Furthermore, the patterns of Gd uptake
and clearance were identical in the tumor-bearing kidney and the
normal kidney with IAUC and CIAUC curves overlapping and thus
indicative of improved blood perfusion in the tumor (Figure 4). Gem-
citabine also changed the pattern of uptake and clearance in the nor-
mal kidney compared with the normal kidney of control mice,
showing a slower washout of Gd (Figure 4B) and a wider IAUC dis-
tribution (Figure 4C ). These data suggest that gemcitabine is also
causing vascular changes in the normal kidney. It should be noted that
vascular changes both in the kidney tumors and in normal kidneys
are consistently observed with one, three, or four doses of gemcitabine.
These findings suggest that one dose of gemcitabine is sufficient to
induce vascular changes that are reproducible with additional treat-
ments of gemcitabine.
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Figure 2. Histology of kidney tumors and normal kidneys from mice treated with sunitinib and gemcitabine. Kidney tumors and normal
contralateral kidneys from mice treated with sunitinib (20 mg/kg), gemcitabine (20 mg/kg), and both combined, obtained on day 28 from
experiments described in Figure 1, were processed for histology and H&E staining. The main findings were labeled on the prints with T
for tumor, V for vessels, G for giant tumor cells. (A) Kidney tumors. Control untreated tumors consisted of tumor cells with large pleomor-
phic nuclei were highly vascularized with a sinusoidal vascular pattern of abnormal enlarged dilated vessels with focal extravasation of
RBCs. Sunitinib (SU)-treated tumors showed thinning and organization of tumor vessels as well as a decrease in the numbers of tumor
vessels. Kidney tumors of mice treated with gemcitabine (Gem) contain numerous abnormal and giant tumor cells with cytoplasmic
vacuoles or eosinophilic inclusions and degenerative changes in nuclei with focal karyopyknosis. Note some of the vessels in these
tumors were still enlarged with foci of RBCs extravasation, however, to a lesser degree than in the untreated tumors. Tumors treated with
sunitinib and gemcitabine (SU + Gem) consisted mostly of abnormal degenerating giant tumor cells. Trimming of tumor vessels was
evident. (B) Normal contralateral left kidneys. The normal kidney from control mice showed intact, regular, and thin blood vessels. Sunitinib
at 20 mg/kg showed a mild effect of dilatation in a few vessels. Gemcitabine caused dilatation of some of the blood vessels. This effect
was milder with combined sunitinib and gemcitabine with fewer vessels dilated. All magnifications, ×40.
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DCE-MRI parametric maps were derived from the C (t) curves for
each pixel and represent the total Gd uptake (AUC) for the tumor
and surrounding kidney tissue (Figure 4E ). Parametric maps from
control mice showed accumulation of Gd in the periphery of the
tumor with no uptake in the tumor core, indicative of poor tumor
perfusion (Figure 4E ), as previously reported [5]. In the normal kid-
ney of control mice, Gd uptake was distributed in the entire kidney
with a higher uptake in the medullary central area than in the periph-
eral cortex, probably reflecting normal secretion of contrast agent
(Figure 4E ). Interestingly, gemcitabine caused striking changes
observed by parametric maps with uptake of Gd in the core of the
tumor, indicative of tumor perfusion (Figure 4E ). The uptake of Gd
in the tumor-bearing kidney was similar to that seen in the normal
kidney (Figure 4E ). These data were consistently reproduced after
one, three, or four treatments of gemcitabine injections (Figure 4E ).
DCE-MRI of Kidney Tumors Treated with Sunitinib
and Gemcitabine
The effect of sunitinib, gemcitabine and both combined on kinet-
ics of Gd uptake and clearance in tumors was evaluated by DCE-
MRI. In this experiment, KCI-18 kidney tumor–bearing mice were
pretreated daily with sunitinib at a dose of 20 mg/kg per day (SU20),
for 3 days on days 10, 11, and 12 after KCI-18 cell implantation in
the right kidney. On day 13, gemcitabine (GEM) was injected i.p. at
20 mg/kg, and this injection was repeated on days 15 and 17 while
continuing daily treatment with SU20. After these three doses of gem-
citabine, on day 18, mice were imaged by DCE-MRI as previously
described [5]. For data analysis, the full kidney was selected as the
ROI for both right tumor-bearing kidney and left normal kidney
(Figure 5A). Analysis of the kinetics of uptake and clearance of Gd
showed that in control mice, the clearance of Gd in the tumor-bearing
kidney was slow compared with faster clearance in the normal kidney
(Figure 5, B-D). After treatment with SU20, the C (t) curves of the
kidney tumors overlapped those of normal kidneys and showed sim-
ilar uptake and improved Gd clearance with much less Gd retention
than that of kidney tumors in control mice (Figure 5B). The tumor-
bearing kidney IAUC curve looked more regular and shifted to the
left compared with control kidney tumors indicating decreased Gd re-
tention (Figure 5C ). Gd uptake and clearance in the C (t) curves,
IAUC and CIAUC showed identical patterns in the tumor-bearing
kidney compared with the normal kidney (Figure 5, B-D). These find-
ings are consistent with our previous studies [5] and suggest a return
to more “normal vasculature” with lower permeability (i.e., less leaky
vessels). After treatment with gemcitabine, the vascular changes de-
scribed in Figure 4 were reproduced in this experiment, including
Figure 3. Histology of spontaneous lung metastases from mice treated with sunitinib and gemcitabine. Lungs from mice treated with
sunitinib (20 mg/kg), gemcitabine (20 mg/kg), and both combined, obtained on day 28 from experiments described in Figure 1, were
processed for histology and H&E staining. The main findings were labeled on the prints with T for tumor, V for vessels, G for giant tumor
cells, F for fibrotic areas, and L for normal lung alveoli. Metastastic lung tumor nodules from untreated mice (Control) consisted of tumor
cells with pleomorphic nuclei and prominent nucleoli and contained areas of dilated vessels. Sunitinib (SU)-treated mice had decreased
number of tumor cells and vessels in lung tumor nodules. Lung tumor nodules from gemcitabine (Gem)- treated mice showed giant
tumor cells with cytoplasmic vacuoles and eosinophilic inclusions and decreased vascularization. Gemcitabine combined with sunitinib
(SU + Gem) contained large eosinophilic areas of hyalinization, fibrosis, and a few giant abnormal tumor cells. Figures were enlarged to
show changes in lung tumor nodules.
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improved clearance of Gd in the tumor-bearing kidney and slower
clearance of Gd in the normal kidney (Figure 5, B-D). After combined
therapy of SU20 with gemcitabine, the patterns of Gd uptake and
clearance resembled those of gemcitabine alone both in kidney tumors
and normal kidneys with a tendency to decreased clearance of Gd (Fig-
ure 5, B-D). As observed for SU20 alone, the IAUC and CIAUC
curves of kidney tumor and normal kidney overlapped and showed
a pattern close to that of normal kidney in control mice (Figure 5,
C and D).
DCE-MRI parametric maps were derived from the C (t) curves for
each pixel and represent the total Gd uptake (AUC) for the tumor
and surrounding kidney tissue (Figure 5E ). As described for Figure 4,
parametric maps from control mice consistently showed accumula-
tion of Gd in the periphery of the tumor with no uptake in the tu-
mor core, indicative of poor tumor perfusion (Figure 5E ). Parametric
maps of SU20-treated mice showed a significant accumulation of Gd
in the tumor-bearing kidney including Gd uptake in the tumor and
also Gd accumulation in the normal kidney (Figure 5E ), as shown
previously [5]. Gemcitabine caused striking changes observed by
parametric maps with tumor perfusion and an uptake of Gd similar
to normal kidney (Figure 5E ), as shown in separate experiments in
Figure 4E . These findings were reproduced with the combined SU20
and gemcitabine including tumor perfusion but less Gd accumula-
tion than that seen with SU20 alone (Figure 5E ).
DCE-MRI Quantitation of Vascular Changes of Kidney
Tumors Treated with Sunitinib and Gemcitabine
To quantitate the vascular changes induced by sunitinib and gem-
citabine and study the reproducibility of our findings, R50 values for
five mice per treatment group were derived from CIAUC curves for
Figure 4. DCE-MRI imaging of vascular changes induced by gemcitabine in KCI-18 kidney tumors. In separate experiments, mice bearing
established kidney tumors were treated with gemcitabine at 20 mg/kg (Gem20) or with vehicle (control). Mice were imaged by DCE-MRI
at 24 hours after gemcitabine treatment after receiving one dose (day 14), three doses (day 18), or four doses (day 21), given 3 days
apart. (A) T1 images: Baseline images before Gd contrast agent injection. The full kidney was selected as the ROI for the tumor-bearing
kidney (blue contour on left of T1 image) and the contralateral normal kidney (red contour on right of T1 image). (B) C (t) kinetics of Gd
contrast uptake and clearance: The first 10 time points represent baseline data. Gd was injected at time point 10, and images were
collected for 20 more time points. (C) IAUC graphs: Data from the C (t) curves were compiled for 16 time points (112 seconds) after Gd
injection to draw IAUC112. The small black bar indicates the peak position of normal kidney in control mice and can be used as a ref-
erence for curve shifting in normal kidneys and kidney tumors treated with gemcitabine. (D) CIAUC graphs: CIAUC curves were derived
from IAUC curves. In panels A, B, C, and D, blue lines are for kidney tumors and pink lines are for normal kidneys. (E) AUC parametric
map: Parametric color maps were constructed based on uptake and concentration of Gd in the tissue, represented by the colors blue,
green, yellow, and red with gradual increase of Gd from lowest values (blue) to highest values (red). The tumor-bearing kidney is on the
left, and the normal contralateral kidney is on the right of the MR images. The color coding in the kidneys are shown for integrated AUC.
Data from a representative mouse from each treatment group are presented.
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both kidney tumors and normal kidneys [5]. The R50 (median) val-
ues correspond to the concentration of Gd at which 50% of the pix-
els have been included (Figure 6A) [5,34]. Lower R50 values were
consistently observed in mice treated with SU20, gemcitabine, and
both combined compared with control mice for kidney tumors (Fig-
ure 6B). Compared with R50 values of normal kidneys in control
mice, a trend to lower R50 was also observed for normal kidneys sug-
gesting a mild systemic effect of both drugs affecting blood flow
(Figure 6C ). To compare the vascular changes induced by the drugs
in kidney tumors to those induced in normal kidneys, R50 values of
kidney tumors were normalized to the R50 values of normal contra-
lateral kidneys for each mouse (NR50 KT vs NK; Figure 6D) [5].
These values were consistently much smaller in mice treated with
each drug and both combined compared with control mice (Fig-
ure 6D). Normalization of R50 values of treated kidney tumors versus
control kidney tumors (NR50 KTtreat vs KTcont) showed negative val-
ues with each drug alone and both combined (Figure 6E ). To assess
the effect of SU20 and gemcitabine on normal contralateral kidneys,
R50 values of normal kidneys from treated mice were normalized to
normal kidneys from control mice (Figure 6F ). These NR50 data of
normal kidneys showed also negative values for mice treated with
each drug separately and both combined (Figure 6F ) but less than
Figure 5. DCE-MRI imaging of vascular changes induced by gemcitabine and sunitinib in KCI-18 kidney tumors. Separate experimental
groups of three mice per group were treated with vehicle only (control), sunitinib only (SU20), gemcitabine only (Gem20), or sunitinib +
gemcitabine (SU20 + Gem20). Mice bearing established kidney tumors were pretreated with sunitinib at 20 mg/kg per day (SU20) for
3 days on days 10 to 12 after KCI-18 cell injection in the kidney. Then, mice received three gemcitabine treatments at 20 mg/kg (Gem20)
given on days 13, 15, and 17 while continuing daily sunitinib treatments. At 24 hours after the last gemcitabine treatment (day 18), mice
were imaged by DCE-MRI for 30 time points at 7-second intervals. (A) T1 images: Baseline images before Gd contrast agent injection.
The full kidney was selected as the ROI for the tumor-bearing kidney (blue contour on left of T1 image) and the contralateral normal
kidney (red contour on right of T1 image). (B) C (t) kinetics of Gd contrast uptake and clearance: The first 10 time points represent base-
line data. Gd was injected at time point 10, and images were collected for 20 more time points. (C) IAUC graphs: Data from the C (t)
curves were compiled for 16 time points (112 seconds) after Gd injection to draw IAUC112. The small black bar indicates the peak po-
sition of normal kidney in control mice and can be used as a reference for curve shifting in normal kidneys and kidney tumors after
treatment. (D) CIAUC graphs: CIAUC graphs were derived from IAUC curves. In graphs B, C, and D, blue lines are for kidney tumors and
pink lines are for normal kidneys. Data from a representative mouse from each treatment group are presented. (E) AUC parametric map:
Parametric color maps were constructed based on uptake and concentration of Gd in the tissue, represented by the colors blue, green,
yellow, and red with gradual increase of Gd from lowest values (blue) to highest values (red). The tumor-bearing kidney is on the left, and
the normal contralateral kidney is on the right of the MR images. The color coding in the kidneys are shown for integrated AUC.
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those of NR50 KTtreat versus KTcont. These data indicate a relatively
mild effect by either drug alone and combined on normal kidney
vasculature (Figure 6F ) in contrast to a more pronounced effect on
vasculature of kidney tumors (Figure 6E ).
Discussion
The concept of normalization of tumor vessel through elimination of
excess endothelial cells to improve the blood flow, reduce vessel leak-
iness and interstitial pressure, and increase drug delivery to tumor
cells has shown promise for combination with anticancer drugs
[37–39]. We have previously determined the doses and schedule of
the antiangiogenic drug sunitinib that cause thinning and regulariza-
tion of tumor vessels in kidney tumors of the KCI-18 RCC ortho-
topic tumor model in nude mice [5]. We found that daily treatment
with 20 mg/kg per day of sunitinib caused better tumor perfusion
and decreased vascular permeability by DCE-MRI [5]. These obser-
vations on vascular changes were in agreement with in situ histologic
studies demonstrating thinning and regularization of tumor vessels
[5]. In addition, this dose caused only mild changes in vessels in nor-
mal kidney tissue and was not toxic to the mice [5]. On the basis of
these findings, the dosage of 20 mg/kg per day of sunitinib was se-
lected to regularize the blood flow in the tumor and then schedule
chemotherapy with gemcitabine. The conditions for combining anti-
angiogenic therapy with chemotherapy were investigated.
Dose-searching studies using 10, 20, or 40 mg/kg of gemcitabine
showed that a schedule of injections given 3 days apart was less toxic
than every 2 days. Doses of 20 and 40 mg/kg gemcitabine were more
effective than 10mg/kg and caused significant kidney tumor growth in-
hibition. To schedule the combination of gemcitabine with sunitinib,
regularization of tumor vessels was monitored by DCE-MRI of kidney
tumor–bearing mice treated with sunitinib only. DCE-MRI showed
that 1 day of sunitinib treatment at a dosage of 20 mg/kg per day
was not sufficient to induce regularization of vasculature and resulted
Figure 6. R50 quantitation of DCE-MRI data of KCI-18 kidney tumors. Mice were treated with vehicle (control, Con), sunitinib at 20 mg/kg
per day (SU), gemcitabine at 20 mg/kg (Gem), or both sunitinib and gemcitabine and were then imaged by DCE-MRI as described in
Figure 5. Data obtained from MR images were quantitated. (A) R50 value calculation: The R50 value is derived from CIAUC curves (as
shown for control mouse) and corresponds to the Gd concentration at which 50% of the pixels have been included. (B) Tumor-bearing
kidney R50: R50 of kidney tumors from five mice per treatment group. (C) Normal kidney R50: R50 normal contralateral kidney for each
mouse shown in B. (D) NR50 of KT versus NK: NR50 represents normalization of R50 values of kidney tumors (KT) relative to R50 values of
normal contralateral kidney (NK) calculated as [R50KT − R50NK] / R50NK for each mouse. (E) NR50 of KTTREAT versus KTCONT: Normalization
of R50 values of kidney tumors from treated mice (KTTREAT) relative to the mean R50 values of kidney tumors from control mice (KTCONT)
calculated as [R50 KTTREAT − R50 KTmean cont] / R50 KTmean cont for each mouse. (F) NR50 of NKTREAT versus NKCONT: Normalization of R50
values of normal kidneys of treated mice relative to the mean R50 values of normal kidneys from control mice calculated as [R50 NKTREAT −
R50 NKmean cont] / R50 NKmean cont for each mouse. Data are presented for five mice per treatment group in each panel.
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only in minor vascular changes (G.G.H., unpublished data, 2010).
However, DCE-MRI of mice treated for 3 days with 20 mg/kg per
day sunitinib confirmed that this schedule was sufficient to induce
vascular changes of decreased Gd retention and improved tumor per-
fusion in KCI-18 kidney tumors, indicating normalization of blood
vessels. Therefore, gemcitabine treatment was initiated after three
consecutive daily treatments of sunitinib. When gemcitabine was ad-
ministered after sunitinib and given at a dose of 20 mg/kg for four
treatments, whereas continuing daily administration of sunitinib, the
effect of the combined therapy was particularly effective causing ap-
proximately 74% reduction in tumor weight by day 28. This schedule
and dosage of sunitinib given in conjunction with gemcitabine were
well tolerated by the mice and were not associated with toxicity. This
combined therapy significantly inhibited the growth of the tumor in
the kidney, and this effect was consistent in all mice tested in con-
trast to greater variability from mouse to mouse with each modality
alone. The size and shape of the tumor-bearing kidneys were com-
parable to those of the normal contralateral kidneys. In agreement
with our gross observations, only small residual tumor nodules sur-
rounded by normal kidney tissue were histologically observed. Tumors
treated with gemcitabine alone or both gemcitabine and sunitinib
showed a high frequency of abnormal giant tumor cells with degen-
erative changes in their cytoplasm and nuclei, indicative of processes
of cell death. Similar effects of the single and combined modalities
were also observed histologically in the spontaneous lung metastases.
In lungs of sunitinib-treated mice, the tumor nodules showed a de-
crease in size, cellularity, and vascularization, probably as a result of
the antiangiogenic activity of sunitinib. Gemcitabine treatment caused
a marked increase in giant tumor cells with degenerative processes in
metastatic lung nodules, which looked identical to those observed in
primary kidney tumors. This effect was more pronounced in lung tu-
mor nodules treated with the combined therapy, as visualized by few
remaining giant tumor cells surrounded by fibrotic areas. The fre-
quency and size of metastatic lung tumor nodules were drastically re-
duced by gemcitabine alone or combined with sunitinib compared
with control mice. These findings observed in spontaneous lung
metastases suggest that sunitinib and gemcitabine act systemically af-
fecting both the primary and metastatic tumors, and therefore, a com-
bined approach of antiangiogenic drug and chemotherapy drug could
be effective for metastatic RCC disease.
Long-term survival studies, using a schedule of 3 days of 20 mg/kg
of sunitinib followed by five treatments of 20 mg/kg of gemcitabine
and continued daily administration of sunitinib resulted in a signifi-
cant increase in mouse survival. Interestingly, although sunitinib daily
treatment was continued after gemcitabine therapy, kidney tumors re-
curred as observed by day 50. These data suggest that 20 mg/kg of
sunitinib was not sufficient to maintain the initial dramatic inhibition
of tumor growth induced by gemcitabine and prevent regrowth of
tumor vessels. It should be noted that the total dose of gemcitabine
(100-120 mg/kg) used in our study is much lower than that used in
pancreatic cancer preclinical models (480 mg/kg) [40]. This low dose
of gemcitabine in our RCC preclinical model is very effective when
combined with an antiangiogenic drug as shown in the pancreatic
cancer model [40]. These data also demonstrate that DCE-MRI is a
useful means to monitor early vascular changes induced by sunitinib to
assess improved blood flow and schedule initiation of chemotherapy.
Recent clinical studies have successfully shown that early changes in
DCE-MRI of cancer patients have the potential to predict response
and guide therapy [41–43].
Our previous observations of uptake and clearance of Gd in control
kidney tumors monitored by DCE-MRI were confirmed in the cur-
rent study [5]. These patterns included slow clearance of Gd and ac-
cumulation of Gd in the periphery of the tumor with no uptake in the
tumor core, as seen in parametric maps. These findings suggested poor
tumor perfusion, probably as a result of leakiness from abnormal en-
larged tumor vessels as observed by histology of tumor sections and
extravasation of RBCs [5]. Imaging of kidney tumor–bearing mice
treated with gemcitabine by DCE-MRI revealed that gemcitabine
caused vascular changes both in the tumors and in normal kidneys.
Kidney tumors treated with gemcitabine showed improved clearance
of the Gd contrast agent relative to the normal contralateral kidney.
Increased tumor perfusion caused by gemcitabine was also observed
by parametric maps showing uptake of Gd in the core of the tumor
in contrast [5]. Histologically, gemcitabine-treated tumors showed a
decrease in the number of enlarged vessels compared with control tu-
mors. These findings on improved tumor perfusion associated with
trimming of the enlarged vessels of the kidney tumors suggest that
gemcitabine also exerted cytotoxic activity on endothelial cells. In ag-
reement with our findings, recent studies demonstrated that endothe-
lial cells are indeed destroyed by gemcitabine both in vitro and in vivo
in an orthotopic preclinical model of pancreatic cancer [44]. These
studies and our findings indicate that the mode of action of gem-
citabine includes not only cytotoxicity to tumor cells but also an anti-
angiogenic effect, thus acting as well on the tumor microenvironment
as shown for sunitinib [44].
Consistent with our previous studies, sunitinib treatment of kid-
ney tumors with 20 mg/kg showed patterns of uptake and improved
Gd clearance by DCE-MRI, comparable to those of normal kidneys,
suggesting a return to more normal vasculature with lower permeabil-
ity (i.e., less leaky vessels) [5]. Histologically, kidney tumors treated
with sunitinib showed considerable thinning, regularization, and orga-
nization of tumor vessels, as previously reported [5]. With the combi-
nation of sunitinib and gemcitabine, the patterns of Gd uptake and
clearance resembled those of gemcitabine alone in both kidney tumors
and normal kidneys, with a tendency to decreased clearance of Gd.
Parametric maps showed increased tumor perfusion. These data were
in agreement with in situ histologic findings, showing tumor vessels
looking more trimmed and organized than those seen after gemcita-
bine treatment alone.
Quantitation of vascular changes induced by sunitinib and gemci-
tabine confirmed the reproducibility of our findings. Lower R50 values
were consistently observed in mice treated with SU20, gemcitabine,
and both combined compared with control mice for kidney tumors.
A trend to lower R50 values was also observed for normal kidneys in
treated mice relative to control mice. These findings were corroborated
by in situ histologic observation of dilatation of some of the vessels in
normal kidney tissue sections. These data indicate a relatively mild sys-
temic effect on normal kidney vasculature mediated by either drug
alone and both drugs combined. This is in contrast to a more pro-
nounced effect of the therapy on kidney tumor vasculature resulting
in increased tumor perfusion and decreased vascular permeability.
Our data suggest that both sunitinib and gemcitabine exert anti-
angiogenic effects in addition to their cytotoxic antitumor activity.
These effects on both the tumor vasculature and tumor cells were
observed in both primary kidney tumors and spontaneous lung me-
tastases, indicating that a combined approach of antiangiogenic drug
and gemcitabine could be effective for metastatic RCC disease. These
studies also emphasize the clinical potential of using DCE-MRI to
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select the dose and schedule of antiangiogenic drugs to schedule che-
motherapy and improve its efficacy.
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